Abveris Again Named as One of the Best Places to Work in 2022
Abveris Named as One of the Best Places to Work
Canton, MA—March 10, 2022—The Business...
Speaker
Ryan Kelly, Director of Business Development
Anti-Idiotypic antibodies (anti-Id) are critical assay reagents used in PK/ADA assays for therapeutic biologics entering clinical trials. Ensuring the timely readiness of high-quality, assay-ready anti-Id is a top-priority task for all bioanalytical groups. In this webinar, the Abveris team will discuss how to de-risk anti-Id discovery in terms of screening platform and strategy selection. In the second of this two-part webinar series, the following topics will be discussed:
1. Challenges for anti-Id discovery for cell-based biologics
2. Case study of an anti-Id discovery campaign for a CAR-T product
Here are more on-demand webinars that our team has put together for you
Overview of screening technologies for anti-Id antibodies discovery.
Dos and don'ts when planning and designing anti-Id discovery campaigns
Case studies of hybridoma-based and Beacon-based anti-Id campaigns targeting therapeutic biologics
Abveris Named as One of the Best Places to Work
Canton, MA—March 10, 2022—The Business...